AUSTIN, Texas , Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding
Phase 3 Study Initiation Still Expected Fall 2021 AUSTIN, Texas , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the U.S.
- Conference Call Today at 9 a.m. ET - AUSTIN, Texas , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2021 .
- Call-in on Tuesday, August 3rd at 9 a.m. ET - AUSTIN, Texas , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the
Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 Months Robust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p
Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 Months Cognition Improved 3.0 Points on ADAS-Cog at 9 Months ( p
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 44% (p=0.02) Respectively Plasma
- On Monday, July 26 th , New Clinical Data for SavaDx to be Shared in a Poster Presentation - - On Thursday, July 29 th , New Clinical Data for Simufilam to be Featured in a Podium Presentation - AUSTIN, Texas , July 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer’s Disease AUSTIN, Texas , June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced
Open-label Study Completes Patient Enrollment Cognition Maintenance Study Initiated May 2020 , now 30% Enrolled 6-month Biomarker Data to be Presented at AAIC Conference in July 9-month Safety & Cognition Data to be Presented at AAIC Conference Clinical Results with SavaDx to be Presented at AAIC
